Background
==========

Gastric cancer is the one of the most common cancer types and is the leading cause of cancer-related death worldwide. Annually, nearly 1 million new cases are diagnosed, and more than 700,000 deaths are estimated to occur from this disease \[[@B1]\]. Increased use of adjuvant and neoadjuvant treatment regimens such as radiotherapy and neoadjuvant chemotherapy has greatly improved both progression-free survival (PFS) and overall survival (OS) \[[@B2]\], and it has been reported that it is possible to deliver neoadjuvant chemotherapy without increasing surgical morbidity and mortality compared with surgery alone \[[@B3]\]. However, it is necessary to find accurate predictors of outcomes for neoadjuvant chemotherapy in order to identify those patients who are more likely to benefit from neoadjuvant chemotherapy. Although a few serum biomarkers have been found to be associated with poor prognosis in patients with gastric cancer \[[@B4],[@B5]\], their use is often time-consuming and expensive. Recently, novel immunological and histological biomarkers have been identified \[[@B6]-[@B8]\]. However, these largely depend on specimens obtained after resection of the primary tumor, and this limits their use in clinical practice prior to surgery.

A systemic inflammatory response has been reported to be associated with the progression of cancer \[[@B9],[@B10]\]. Coussens *et al*. \[[@B9]\] reported that the ability of a tumor to invade and metastasize was dependent on the intrinsic characteristics of the tumor cells, as well as the tumor microenvironment. Peripheral blood tests at the time of diagnosis and treatment can reflect inflammatory conditions within the tumor. Evaluation of peripheral blood parameters including C-reactive protein (CRP), leukocytes, neutrophil, lymphocyte, monocyte, and platelet counts, as well as the modified Glasgow Prognostic Score (mGPS), neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR), have been proposed as prognostic factors for patients with various types of malignancies. An elevated serum CRP level was associated with poor survival in patients with gastro-esophageal cancer \[[@B11]\], ovarian cancer \[[@B12]\], and renal cancer \[[@B13]\], while elevated neutrophil, monocyte, and leukocyte counts have been reported to be associated with poor survival in patients with metastatic melanoma \[[@B14],[@B15]\]. A high pre-operative NLR has been identified as a useful and convenient predictor of survival in patients with gastric cancer \[[@B16]-[@B20]\], colorectal cancer \[[@B21],[@B22]\] and advanced non-small-cell lung cancer \[[@B23]\]. Recently, Dutta S *et al*. \[[@B24]\] reported that the mGPS was independently associated with cancer-specific survival in patients undergoing potentially curative resection of gastric cancer, and an increase in the mGPS was associated with higher NLR and poorer survival. However, the usefulness of NLR in patients with advanced malignancies receiving neoadjuvant chemotherapy has been reported only rarely \[[@B25]-[@B27]\]. Kunisaki C *et al*. \[[@B25]\] found that there were significant correlations between the GPS and NLR in patients with advanced gastric cancer receiving biweekly docetaxel and S-1 combination chemotherapy, and patients with low GPS group may obtain favorable outcomes with chemotherapy. An analysis conducted by Kishi *et al*. \[[@B26]\] showed that a high NLR independently predicted poor survival in patients with colorectal liver metastases treated with chemotherapy followed by resection or chemotherapy alone, and that normalization of the high NLR by neoadjuvant chemotherapy indicated improved survival.

To our knowledge, the prognostic significance of pre-treatment NLR including pre-chemotherapy and pre-operative NLR have not been evaluated in advanced gastric cancer treated with neoadjuvant chemotherapy. The aim of the present study was to evaluate the prognostic significance of pre-chemotherapy and pre-operative NLR in peripheral blood samples from patients with stage III-IV gastric cancer receiving neoadjuvant chemotherapy. In addition, we determined whether neoadjuvant chemotherapy normalized high pre-chemotherapy NLR, and assessed the effect of NLR normalization on survival.

Methods
=======

Ethics approval
---------------

The study was approved by the ethics committee of the First Affiliated Hospital, Medical College, Zhejiang University, and prior to the research, informed consent was obtained from all patients.

Patients
--------

In total, 58 patients diagnosed with advanced gastric cancer and treated with neoadjuvant chemotherapy in the Department of Gastrointestinal Surgery, First Affiliated Hospital, Medical College, Zhejiang University were enrolled in this study between July 2004 and May 2009. All patients fulfilled the following criteria: locally advanced, T3-T4 carcinoma staged according to the sixth edition of the American Joint Committee on Cancer (AJCC) guidelines, without distant metastases; no previous chemotherapy or radiotherapy; and adequate hematological, liver and renal function. Of the 58 patients, 3 had not undergone gastrectomy (2 had undergone opening and closure, and one had undergone palliative gastrojejunostomy), 3 had been diagnosed with other malignancies simultaneously (2 with rectal cancer and 1 with lung cancer), and another 2 patients showed evidence of infection at the time of blood sampling, thus ultimately, 50 patients were eligible for inclusion in this study.

Patients were treated with one of two neoadjuvant chemotherapy regimens: oxaliplatin plus capecitabine (XELOX) or oxaliplatin plus 5-fluorouracil (5-FU) plus leucovorin (FOLFOX). As there were no significant differences between the two chemotherapy regimen groups regarding either median PFS (26 versus 30 months; *P* = 0.991; Figure [1](#F1){ref-type="fig"}A) or median OS (36 versus 34 months; *P* = 0.845; Figure [1](#F1){ref-type="fig"}B), data from both groups were combined in this study. For 4 of the 50 eligible patients, data on blood parameters before surgery were not available (missing data \<10%). Thus, data from 46 patients were analyzed in the present study.

![**Survival of patients treated with different neoadjuvant chemotherapy regimens.** (**A**) Progression-free survival and (**B**) overall survival.](1477-7819-11-112-1){#F1}

Blood parameters
----------------

Venous blood samples were taken at the time of diagnosis before neoadjuvant chemotherapy, and 4 weeks or more after the last dose of chemotherapy and within 1 week before surgery (when hematotoxicity had been minimized). NLR was defined as neutrophil count divided by lymphocyte count. The cut-off values for white blood cells (\>6,000/mm^3^ and ≤6,000/mm^3^), neutrophils (\>4,000/mm^3^ and ≤4,000/mm^3^), lymphocytes (\>1,500/mm^3^ and ≤1,500/mm^3^), monocytes (\>500/mm^3^ and ≤500/mm^3^) and NLR (\>2.5 and ≤2.5) were defined using the median values and data from previous studies \[[@B17]\].

Statistical analysis
--------------------

Response rates were evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines \[[@B28]\]. Clinical response was defined as either complete response (CR) or partial response (PR), and non-response as either stable disease (SD) or progressive disease (PD). Clinical benefit was defined as CR, PR or SD, and no benefit was defined as PD. The follow-up period commenced at the start of neoadjuvant chemotherapy with a censor date of April 2012. PFS was calculated from the date of initiation of neoadjuvant chemotherapy until objective tumor progression, death, or last contact. OS was calculated from the date of initiation of neoadjuvant chemotherapy until death or last contact. Potential prognostic factors were age, gender, tumor site, clinical response, clinical benefit, type of surgery, radicality of surgery, tumor differentiation, and peripheral blood parameters; these were entered into a univariate analysis using the Kaplan--Meier analysis model and differences between groups were compared by log-rank test. Prognostic factors with significance values of *P*\<0.10 in the univariate analysis were entered into a multivariate analysis, which was performed using Cox proportional hazards model with the backward likelihood method to test for independent prognostic variables.

All statistical analyses were performing using SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA), and in all analyses, a value of *P* \<0.05 was considered to indicate statistical significance.

Results
=======

Patient characteristics
-----------------------

Table [1](#T1){ref-type="table"} shows the characteristics of the 46 patients: 36 were male and 10 were female, with a median age of 60 years (range 37--77 years). Of the 46 patients, 32 received a XELOX neoadjuvant chemotherapy regimen and 14 patients received a FOLFOX regimen. The median number of chemotherapy cycles was three (range one to five). All 46 patients underwent gastrectomy; 28 (60.9%) underwent total gastrectomy and 18 (39.1%), subtotal gastrectomy, with 1 patient receiving combined resection of the transverse colon. Clinical and pathological TNM (tumor, node, metastasis) classification based on the AJCC staging were as follows: clinical TNM classification showed that 40 patients had stage III disease and 6 had stage IV disease, while pathological TNM classification based on specimens obtained after resection of the primary tumor showed that 23 patients had stage III disease and 11 had stage IV disease.

###### 

Demographic and clinicopathological characteristics of 46 patients with gastric cancer

  **Parameter**                            **Number (%)**
  ---------------------------------------- ----------------
  Age, years                                
   \>65                                    14 (30.4%)
   ≤65                                     32 (69.6%)
  Gender                                    
   Male                                    36 (78.3%)
   Female                                  10 (21.7%)
  Chemotherapy regimen                      
   XELOX                                   32 (69.6%)
   FOLFOX                                  14 (30.4%)
  Cycles of chemotherapy, median (range)   3 (1--5)
  Primary tumor site                        
   Upper 1/3                               12 (26.1%)
   Middle 1/3                              12 (26.1%)
   Low 1/3                                 22 (47.8%)
  Clinical response^a^                      
   Yes                                     21 (45.7%)
   No                                      25 (54.3%)
  Clinical benefit^b^                       
   Yes                                     43 (93.5%)
   No                                      3 (6.5%)
  Types of surgery                          
   Total                                   28 (60.9%)
   Subtotal                                18 (39.1%)
  Radicality                                
   R0                                      37 (80.4%)
   R1                                      0
   R2                                      9 (19.6%)
  Combined resection                        
   No                                      45 (97.8%)
   Yes                                     1 (2.2%)
  Differentiation                           
   Differentiated^c^                       15 (32.6%)
   Poorly differentiated^d^                31 (67.4%)
  Clinical TNM classification^e^            
   T stage                                  
    T3                                     40 (87%)
    T4                                     6 (13%)
   N stage                                  
    N1                                     14 (30.4%)
    N2                                     32 (69.6%)
    N3                                     0
   TNM stage                                
    III                                    40 (87%)
    IV                                     6 (13%)
  Pathological TNM classification^e^        
   y T stage^f^                             
    T0                                     2 (4.3%)
    T1                                     1 (2.2%)
    T2                                     6 (13%)
    T3                                     28 (60.9%)
    T4                                     9 (19.6%)
   y N stage^f^                             
    N0                                     8 (17.4%)
    N1                                     19 (41.3%)
    N2                                     13 (28.3%)
    N3                                     6 (13%)
   y TNM stage^f^                           
    Tis                                    1 (2.2%)
    I                                      3 (6.5%)
    II                                     8 (17.4%)
    III                                    23 (50%)
    IV                                     11 (23.9%)

CR, complete response, PD, progressive disease; PR, partial response; SD, stable disease; Tis, tumor *in situ*; TNM, tumor, node metastasis;

^a^Clinical response: Yes means CR and PR; No means SD and PD.

^b^Clinical benefit: Yes means CR and PR and SD; No means PD.

^c^Well and moderately differentiated adenocarcinoma.

^d^Poorly differentiated adenocarcinoma, ring cell carcinoma.

^e^American Joint of Committee On Cancer, sixth edition.

^f^Classification after neoadjuvant chemotherapy.

Blood parameters
----------------

The median pre-chemotherapy white blood cell, neutrophil, lymphocyte, and monocyte counts were 6,400, 3,900, 1,550, and 500 per mm^3^, respectively. The median pre-chemotherapy NLR was 2.74 (range 0.91 to 7.00), and the median pre-operative NLR was 2.35 (range 0.70 to 6.00). An NLR value of 2.5 was used as the cut-off value to classify patients into high (\>2.5) or low (≤2.5) NLR groups.

Prognostic variables for PFS and OS
-----------------------------------

For the 46 patients, the median PFS was 26.0 months, and the median OS was 34.0 months. In univariate analysis, variables predicting improved PFS were R0 resection, well and moderately differentiated tumor, pre-chemotherapy neutrophil count of 4,000/mm^3^ or less, pre-chemotherapy NLR 2.5 or less, pre-operative neutrophil count 4,000/mm^3^ or less, and pre-operative NLR 2.5 or less (Table [2](#T2){ref-type="table"}). The following variables were associated with improved OS: R0 resection, well and moderately differentiated tumor, pre-operative neutrophil count 4,000/mm^3^ or less and pre-operative NLR 2.5 or less (Table [3](#T3){ref-type="table"}). The pre-chemotherapy parameters appeared to have no prognostic values on OS (pre-chemotherapy neutrophil count *P* = 0.154; pre-chemotherapy NLR *P* = 0.113) (data not shown). Meanwhile, we found that pre-chemotherapy and pre-operative lymphocyte count had no prognostic significance using the cut-off value of 1500/mm^3^ on PFS (pre-chemotherapy lymphocytes *P* = 0.803; pre-operative lymphocytes; *P* = 0.615) or OS (pre-chemotherapy lymphocytes *P* = 0.744; pre-operative lymphocytes *P* = 0.647) in univariate analysis (data not shown). Median PFS and median OS were worse for patients with high NLR values than for those with low NLR values before chemotherapy (median PFS 16 months and 49 months, respectively, *P* = 0.012; median OS 21 months and 52 months, *P* = 0.113) (Figure [2](#F2){ref-type="fig"}A,B). Worse median PFS and median OS was also seen in patients with high NLR values than those with low NLR values after neoadjuvant chemotherapy but before surgery (median PFS 12 months *and* 35 months, respectively; *P* = 0.019; median OS 21 months versus 52 months; *P* = 0.082) (Figure [3](#F3){ref-type="fig"}A,B). Multivariate analysis identified high pre-chemotherapy NLR (*P* = 0.033, hazard ratio (HR) = 2.329, 95% CI 1.069 to 5.073) and high pre-operative NLR (*P* = 0.022, HR = 2.347, 95% CI 1.128 to 4.881) as independent factors associated with worse PFS (Table [2](#T2){ref-type="table"}), but both lost independent prognostic significance for OS upon multivariate analysis (Table [3](#T3){ref-type="table"}).

![**Kaplan-Meier survival curves according to neutrophil-lymphocyte ratio (NLR) before neoadjuvant chemotherapy.** (**A**) Progression-free survival and (**B**) overall survival. *P* values were determined using the log-rank test.](1477-7819-11-112-2){#F2}

![**Kaplan-Meier survival curves according to neutrophil-lymphocyte ratio (NLR) before surgery.** (**A**) Progression-free survival and (**B**) overall survival. *P* values were determined using the log-rank test.](1477-7819-11-112-3){#F3}

###### 

Results of the univariate and multivariate analyses of progression-free survival in 46 patients with stage III-IV gastric cancer treated with neoadjuvant chemotherapy

  **Factors**                         **Number**    **Univariate analysis**^**a**^**,*P*value**   **Multivariate analysis**^**b**^**,**  
  ----------------------------------- ------------ --------------------------------------------- --------------------------------------- ---------
  Radicality                                                                                                                                  
   R0                                 37                                                                 0.163 (0.063 to 0.421)           \<0.001
   R1                                                                                                                                         
   R2                                 9                               \<0.001                                       1                         
  Differentiation                                                                                                                             
   Differentiated^c^                  15                                                                                                      
   Poorly differentiated^d^           31                               0.039                                                                  
  Pre-chemotherapy blood parameters                                                                                                           
   Neutrophils, cells/mm^3^                                                                                                                   
    ≤4000                             24                                                                                                      
    \>4000                            22                               0.065                                                                  
   NLR                                                                                                                                        
    ≤2.5                              22                                                                            1                         
    \>2.5                             24                               0.012                             2.329 (1.069 to 5.073)            0.033
  Pre-operative blood parameters e                                                                                                            
   Neutrophils, cells/mm^3^                                                                                                                   
    ≤4000                             34                                                                                                      
    \>4000                            12                               0.049                                                                  
   NLR                                                                                                                                        
    ≤2.5                              26                                                                            1                         
    \>2.5                             20                               0.019                             2.347 (1.128 to 4.881)            0.022

HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.

^a^Performed using the Kaplan-Meier analysis model and log-rank test; values of *P*\<0.10 in the univariate analysis were entered into a multivariate analysis.

^b^Performed using Cox proportional hazards models with the backward likelihood method.

^c^Differentiated include: well and moderately differentiated adenocarcinoma.

^d^Poorly differentiated include: poorly differentiated adenocarcinoma, ring cell carcinoma.

###### 

Results of the univariate and multivariate analyses of overall survival in 46 patients with stage III-IV gastric cancer treated with neoadjuvant chemotherapy

  **Factors**                      **Number**    **Univariate analysis**^**a**^**,*P*value**   **Multivariate analysis**^**b**^  
  -------------------------------- ------------ --------------------------------------------- ---------------------------------- ---------
  Radicality                                                                                                                          
   R0                              37                                                               0.127 (0.050 to 0.320)        \<0.001
   R1                                                                                                                                 
   R2                              9                               \<0.001                                    1                       
  Differentiation                                                                                                                     
   Differentiated^c^               15                                                                                                 
   Poorly differentiated^d^        31                               0.061                                                             
  Pre-operative blood parameters                                                                                                      
   Neutrophils, cells/mm^3^                                                                                                           
    ≤4000                          34                                                                                                 
    \>4000                         12                               0.037                                                             
   NLR                                                                                                                                
    ≤2.5                           26                                                                                                 
    \>2.5                          20                               0.082                                                             

HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.

^a^Performed using the Kaplan-Meier analysis model and log-rank test; values of *P* \<0.10 in the univariate analysis were entered into a multivariate analysis.

^b^Performed using Cox proportional hazards models with the backward likelihood method.

^c^Well and moderately differentiated adenocarcinoma.

^d^Poorly adenocarcinoma, ring cell carcinoma.

Normalization of pre-chemotherapy NLR and correlation with PFS and OS
---------------------------------------------------------------------

Of the 46 patients, 24 had NLR values above 2.5 before chemotherapy, and 11 of these had NLR values of 2.5 or less before surgery. Of the 22 patients with NLR values of 2.5 or less before chemotherapy, 7 had NLR values above 2.5 before surgery. The 11 patients with NLR normalization had better median PFS (35.0 versus 10.0 months; *P* = 0.003) and better median OS (60 versus 16 months; *P* = 0.042) than the 13 patients with NLR values above 2.5 before both chemotherapy and surgery, and similar median PFS (35 versus 49 months; *P* = 0.648 ) and median OS (60 versus 42 months; *P* = 0.869) as the 15 patients with NLR of 2.5 or less before both chemotherapy and surgery (Table [4](#T4){ref-type="table"}).

###### 

Survival of patients according to neutrophil-lymphocyte ratio (NLR) before both neoadjuvant chemotherapy and surgery

  **NLR changed by chemotherapy**^**a**^   **Number**   **PFS**     **OS**                       
  ---------------------------------------- ------------ ----------- -------- ---- --------- ---- -------
  NLR \>2.5                                →            NLR \>2.5   13        10             16      
  NLR ≤2.5                                 →            NLR ≤2.5    15        49   \<0.001   42   0.015
  NLR \>2.5                                →            NLR ≤2.5    11        35             60      
  NLR ≤2.5                                 →            NLR ≤2.5    15        49    0.648    42   0.869
  NLR \>2.5                                →            NLR ≤2.5    11        35             60      
  NLR \>2.5                                →            NLR \>2.5   13        10    0.003    16   0.042

NLR, Neutrophil to lymphocyte ratio.

^a^Change between pre-chemotherapy and pre-operative NLR.

Discussion
==========

Gastric cancer is one of the most common types of malignancies worldwide, leading to hundreds of thousands of deaths annually. Multimodal therapy, including radiotherapy, adjuvant chemotherapy, and targeted therapy, has greatly improved the survival of patients with advanced gastric cancer. Neoadjuvant chemotherapy is currently in the limelight, with verification of its efficacy and safety now under way \[[@B29]\]. However, in order to select the optimal treatment regimen for individuals, accurate predictors that identify those patients who are more likely to benefit from neoadjuvant chemotherapy are needed.

Peripheral blood samples can be easily obtained for pre-treatment prediction. Several studies have established systemic inflammation-based prognostic scores before surgery \[[@B30]-[@B33]\]. A study conducted by Proctor *et al*. \[[@B31]\], which enrolled 8,759 patients diagnosed with a variety of cancers showed that the systemic inflammation-based scores, including the mGPS, NLR, PLR, Prognostic Index, and Prognostic Nutritional Index, have prognostic value. In particular, NLR has been reported to be a useful prognostic factor in gastric cancer \[[@B16]-[@B20]\]. Hirashima *et al*. \[[@B16]\] first suggested that high NLR was associated with poor OS in patients with early gastric cancer, and Jung *et al*. \[[@B20]\] showed that raised pre-operative NLR predicted poor disease-free survival and OS following resection for late-stage gastric cancer. However, to our knowledge, the prognostic significance of NLR in patients with advanced gastric cancer receiving neoadjuvant chemotherapy has rarely been studied. We analyzed the relationship between pre-chemotherapy and pre-operative NLR scores and survival in patients with stage III-IV gastric cancer. In addition, we evaluated whether neoadjuvant chemotherapy normalized high NLR, and evaluated the effect of such NLR normalization on survival.

Our results showed that high pre-chemotherapy NLR and high pre-operative NLR independently predicted worse PFS in patients with stage III-IV gastric cancer receiving neoadjuvant chemotherapy, and that high NLR pre-operative was associated with poor OS in univariate analysis. Although high pre-operative NLR lost its independent prognostic significance for OS in multivariate analysis, it still provided important information on NLR for clinical practice. A study by Kishi *et al.*\[[@B26]\] suggested that high NLR was a useful predictor of worse survival in patients with colorectal liver metastases treated with chemotherapy alone or with chemotherapy followed by hepatic resection, and our findings are consistent with this study. Kishi *et al*. also demonstrated that normalization of high NLR by chemotherapy indicated improved survival. In our study, we found that high NLR values were normalized after neoadjuvant chemotherapy in 11 patients, and that normalization of high NLR indicated improved PFS and OS, with patients in whom it occurred having similar survival to those with low NLR before both chemotherapy and surgery.

The association between elevated NLR and poor survival in patients with various types of cancers has not been clearly defined until now. It is possible that pre-treatment neutrophil and lymphocyte numbers indicate the level of inflammation within the tumor, and thus predict prognosis. Indeed, there are several possible explanations for this. Cytokines generated by neutrophils, such as vascular endothelial growth factor, interleukin-18 and matrix metalloproteinases \[[@B34]-[@B36]\], may establish a microenvironment that promotes angiogenesis, and thus promotes tumor growth and metastasis. In addition, the increased number of neutrophils around the tumor may suppress the anti-tumor immune responses of natural killer cells and activated T cells \[[@B37],[@B38]\]. At the same time, a reduced number of lymphocytes may weaken the lymphocyte-mediated anti-tumor cellular immune response. Hence, it is likely that the combined effects of neutrophilia and lymphocytopenia lead to a high NLR and thus promote angiogenesis and inhibit anti-tumor reactivity, ultimately leading to tumor growth and progression.

To our knowledge, this is the first study of the associations of pre-chemotherapy and pre-surgery NLR values with PFS and OS in patients with advanced gastric cancer receiving neoadjuvant chemotherapy. Notably, we evaluated the prognostic significance of NLR normalization due to neoadjuvant chemotherapy for survival. Thus, the present study may provide important information for clinical practice. However, as our study was retrospective and the number of patients was small, larger numbers of patients with advanced gastric cancer treated with neoadjuvant chemotherapy should be enrolled in a well-designed prospective study. Although the peripheral blood samples were obtained 4 weeks after the last dose of chemotherapy, when hematotoxicity had been minimized, its influence could not be excluded completely. Moreover, whether the cut-off value of 2.5 for NLR is correct requires further investigation.

Conclusions
===========

NLR could be a convenient, easily measured prognostic indicator for patients with stage III-IV gastric cancer treated with neoadjuvant chemotherapy. Patients with high pre-treatment NLR values need multimodal therapy, and normalization of high NLR by neoadjuvant chemotherapy indicates a good chemotherapy response rate and improved survival. Pre-treatment NLR may help clinicians to identify those patients who will benefit from neoadjuvant chemotherapy, and normalization of NLR by chemotherapy may represent a good prognostic indicator. However, further studies involving greater numbers of patients with gastric cancer are required.
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